Navigation Links
CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting
Date:11/7/2013

less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

CTI is pursuing a broad approach to advancing pacritinib for patients with myelofibrosis by conducting two Phase 3 clinical trials:  one in a broad set of patients without limitations on blood platelet counts, the PERSIST-1 trial, and the other will be in patients with low platelet counts, the PERSIST-2 trial, which is expected to begin in the fourth quarter of 2013.  In October 2013, we reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment, or SPA, for the PERSIST-2 pivotal trial.  A SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application, or NDA, submission.  

About Tosedostat

Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials.  CTI has exclusive marketing and co-development rights to Chroma Therapeutics Ltd.'s drug candidate tosedostat in North, Central and South America.

About Cell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable.  CTI is headquartered in Seattle, WA.  For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.  Such statements are s
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ambit Biosciences Announces Third Quarter 2013 Operating Results
2. Spherix Announces the Closing of Private Placement of $2,235,000
3. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
4. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
5. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
6. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
7. AVS announces its major award winners of 2013
8. Metabolix Announces Third Quarter 2013 Financial Results
9. Discovery Labs Announces Completion of $50 Million Public Offering
10. Life Technologies Announces Third Quarter 2013 Results
11. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary combined ... the specialized Wolvega Horse Clinic. , Due to a ... ruptured 90% and her deep digital flexor tendon 50%. ... for a horse. , The clinic has performed numerous ... This revolutionary regenerative option for ruptured tendons has only ...
(Date:9/19/2014)... use light, rather than electricity, to move data ... efficiency is a growing concern as chips, transistor ... of optical circuits light emitters, modulators, and ... One promising light source for optical chips is ... when deposited as a single, atom-thick layer. Other ...
(Date:9/19/2014)... 2014  Nektar Therapeutics (NASDAQ: NKTR ... the analgesic profiles of a series of the ... molecules. The preclinical research candidates were created using ... The analgesic properties of kappa receptor agonism ... Kappa opioid receptors are expressed in the ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... REYKJAVIK, Iceland, August 10 deCODE genetics,(Nasdaq: ... the,quarter ended June 30, 2009. A conference call to ... will be webcast live tomorrow,Tuesday, August 11, at 8:00am ... , The financial results presented ...
... BOZEN, Italy, August 10 , ... Health Robotics today announced that it has signed ... Robot. The,agreement enables McKesson to achieve its goal of safely, ... "We are very pleased to have ...
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... sale of approximately 2.28 million shares of its common stock ... stock for gross proceeds of approximately $15.0 million on August ... per unit (each unit consisting of one share and a ...
Cached Biology Technology:deCODE genetics Announces Second Quarter 2009 Financial Results 2deCODE genetics Announces Second Quarter 2009 Financial Results 3deCODE genetics Announces Second Quarter 2009 Financial Results 4deCODE genetics Announces Second Quarter 2009 Financial Results 5deCODE genetics Announces Second Quarter 2009 Financial Results 6deCODE genetics Announces Second Quarter 2009 Financial Results 7deCODE genetics Announces Second Quarter 2009 Financial Results 8deCODE genetics Announces Second Quarter 2009 Financial Results 9deCODE genetics Announces Second Quarter 2009 Financial Results 10McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 2McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. Therapy 3Oncothyreon announces closing of $15.0 million registered direct financing 2
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
(Date:9/18/2014)... spend their entire lives nestling in the protective tentacles ... babies they sometimes travel hundreds of kilometres across the ... reef fish has been predicted, this is the first ... distant populations has been observed. , Dr Steve Simpson, ... the University of Exeter, and colleagues from the Australian ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... professors are leading research teams that will work ... and the Caribbean to increase food production, improve ... change. The projects are part of the Sustainable ... Program (SANREM CRSP), a $15 million, five-year program ...
... study from Children,s Hospital Boston and the Boston-based Autism Consortium ... known as chromosomal microarray analysis, has about three times the ... (ASDs) than standard tests. Publishing in the April issue of ... that CMA become part of the first-line genetic work-up for ...
... WINSTON-SALEM, N.C. Vitamin D is quickly becoming the "go-to" ... to atherosclerosis. However, new evidence from a Wake Forest University ... those with low levels may have different effects based on ... do harm. The study is the first to ...
Cached Biology News:Researchers introducing sustainable agriculture practices to improve food security 2Researchers introducing sustainable agriculture practices to improve food security 3A better genetic test for autism 2A better genetic test for autism 3Vitamin D levels have different effects on atherosclerosis in blacks and whites 2Vitamin D levels have different effects on atherosclerosis in blacks and whites 3
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
... Protocol Development ,Probe Titer and ... DNA Screenings in Animal or ... Labeling of RNA / Protein ... and DNA Localization in Transgenic ...
Biology Products: